Webcast Alert: Aastrom Biosciences Announces Its Third Quarter Investor Conference Call
05 May 2006 - 4:00AM
Business Wire
Aastrom Biosciences, Inc. (NASDAQ:ASTM) announces the following
Webcast: What: Aastrom Biosciences, Inc. Third Quarter Fiscal Year
End 2006 Investor Conference Call When: Wednesday, May 10, 2006 @
11:00 am (EDT) Where: http://www.vcall.com/IC/CEPage.asp?ID=104209
How: -- For live Internet access, simply log on to the web at the
address above. -- For phone access, interested parties should call
toll-free (877) 407-9205 before the start of the call to register
and identify themselves as registrants of the "Aastrom Conference
Call". Any registered caller on the toll-free line may ask for call
operator for directions to be placed in the queue for the Question
& Answer session. If calling from outside the U.S., please use
the international phone number (201) 689-8054. -- To download the
podcast, simply log on to the web at the address above. Contact:
Kris Maly, Investor Relations Department, (734) 930-5777 or
mail@aastrom.com If you are unable to participate during the live
call, the webcast will be available for replay at
http://www.investorcalendar.com/ for 60 days. Through May 20, 2006,
the audio replay of the call will be available by dialing toll-free
(877) 660-6853, or from outside the U.S. (201) 612-7415. When
prompted on the phone, the Account # is: 286, and the Conference
ID# is: 201274. Aastrom Biosciences, Inc. (Nasdaq: ASTM) is
developing products for the repair or regeneration of multiple
human tissues, based on its proprietary Tissue Repair Cell (TRC)
adult stem cell technology. Aastrom's TRC products contain large
numbers of stromal, stem and progenitor cells that are produced
from a small amount of bone marrow cells originating from the
patient. The AastromReplicell(R) System, an industry-unique
automated cell product manufacturing platform, was developed for
the production of standardized, patient-specific TRC products. TRC
products have been used safely in humans as a substitute for bone
marrow stem cells, and are currently in clinical trials for bone
grafting (long bone fractures and spine fusion) and blood vessel
regeneration (diabetic limb ischemia) applications. The Company has
recently reported positive interim clinical trial results for its
TRCs demonstrating both the clinical safety and ability of TRCs to
induce healthy new tissue growth (long bone fractures and jaw bone
reconstruction). Most recently, the Company's proprietary TRCs
received an Orphan Drug Designation from the U.S. Food and Drug
Administration (FDA) for use in the treatment of osteonecrosis of
the hip. For more information, visit Aastrom's website at
www.aastrom.com.
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024